Clinical trials: Lung Neoplasms, Non-Small Cell Lung Cancer
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Non-Small Cell Lung Cancer Stage, Chemoradiation
Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer
The aim of this study is to evaluate the feasibility and the effect of daily, individual, supervised and structured exercise training before radiotherapy in patients diagnosed with Non-Small Cell Lung Cancer.
- Trial name
- PRIME (NCT03066271)
- Testing
- Exercise +, Control +
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
This phase I/II clinical trial evaluates the safety, efficacy, and prognostic potential of [18F]AlF-NOTA-PCP2 PET/CT imaging in assessing PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell…
- Conditions
- Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
- Trial name
- PD-L1-PET (NCT06690216)
- Testing
- PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Man Hu
Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired.
- Conditions
- Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer, Lung Cancer
- Trial name
- NCT07104630
- Testing
- Pulmonary Rehabilitation (PR), No intervention: Usual care
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
The primary objective of this trial is to compare the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with carboplatin to those treated with paclitaxel plus…
- Trial name
- NCT00243867
- Testing
- Taxoprexin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 518 people
- Sponsor
- American Regent, Inc.
NSCLC Stage IV
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Trial name
- NCT04633564
- Testing
- Bevacizumab as MYL-1402O, Bevacizumab as Avastin
- Where
- 102 sites in Belarus, Bosnia and Herzegovina and 15 more
- Volunteers
- 671 people
- Sponsor
- Mylan Pharmaceuticals Inc
Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03948763
- Testing
- V941, Pembrolizumab
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Non Small Cell Lung Cancer
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
- Trial name
- FORTIS-M (NCT00707304)
- Testing
- Talactoferrin
- Where
- 189 sites in United States, Australia and 21 more
- Volunteers
- 742 people
- Sponsor
- Agennix
Squamous-cell Non-Small-cell Lung Cancer
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
This is a phase 3 double-blinded randomized multicenter clinical trial of SCT-I10A or placebo plus docetaxel with previously treated squamous cell non-small cell lung cancer patients.
- Trial name
- NCT04171284
- Testing
- SCT-I10, Docetaxel
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sinocelltech Ltd.
Carcinoma, Non-Small-Cell Lung
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins…
- Trial name
- NCT01909752
- Testing
- Cyclophosphamide, DRibble vaccine, Imiquimod
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UbiVac
Carcinoma, Non-Small-Cell Lung, Sleep Wake Disorders
Low-Frequency rTMS for In-Hospital Sleep Disturbance in Advanced NSCLC
This randomized, double-blind, sham-controlled trial will evaluate whether low-frequency repetitive transcranial magnetic stimulation (rTMS) can improve in-hospital sleep quality in adults with advanced non-small cell lung cancer…
- Trial name
- NCT07796438
- Testing
- Active Low-Frequency Repetitive Transcranial Magnetic Stimulation
- Volunteers
- 160 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Lung Cancer
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed.
- Trial name
- NCT00104728
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Fungal Diseases, Lung Cancer (NSCLC)
Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance
This study aims to uncover the characteristics of the fungal flora in non-small cell lung cancer, and to investigate the relationship between pulmonary fungi and the various pathological subtypes, stages, clinical features of…
- Conditions
- Fungal Diseases, Lung Cancer (NSCLC), Microbioata
- Trial name
- NCT07783971
- Where
- China
- Volunteers
- 10 people
- Sponsor
- 958th Army Hospital of the Chinese People's Liberation Army
NSCLC, Stage I
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
This is a prospective, open, single-center, single-arm phase II clinical study with common EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory.To evaluate the efficacy and safety of adjuvant…
- Trial name
- NCT05686434
- Testing
- Osimertinib
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Stage IIIA Non-small Cell Lung Cancer
Pathological Response After Neoadjuvant Treatment on NSCLC
This is a non-interventional, observational, multicenter and retrospective study. Being limited to the collection of patient data already filled in the Tumor Thoracic Registry data base and the data from stage IIIA clinical…
- Trial name
- PLANET (NCT05167487)
- Testing
- Cisplatin, Carboplatin
- Where
- 17 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Fundación GECP
Non-small-cell Lung Cancer
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
The purpose of this study is to evaluate the overall response rate and disease free survival for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation.
- Trial name
- NCT01843647
- Testing
- Icotinib, Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Carcinoma of Lung
Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor.
Current oncological treatment for patients with locally advanced lung cancer comprise adjuvant immunotherapy (immune checkpoint inhibitors-ICI) as an additional one-year treatment after chemoradiotherapy which increases overall…
- Trial name
- NCT07754409
- Where
- Sweden
- Volunteers
- 75 people
- Sponsor
- Göteborg University
Non Small Cell Lung Cancer
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
This is single-arm, open-label study design. Patients will receive brigatinib until disease progression, unacceptable toxicity, withdrawal of consent, of death.
- Trial name
- NCT04074993
- Testing
- Brigatinib
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- JI-YOUN HAN